Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Accelerate Diagnostics logo

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$1.18
52-Week Range
N/A
Volume
53.64 million shs
Average Volume
562,314 shs
Market Capitalization
$857 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Accelerate Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

AXDX MarketRank™: 

Accelerate Diagnostics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for AXDX.
  • Dividend Yield

    Accelerate Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Accelerate Diagnostics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AXDX.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Accelerate Diagnostics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Accelerate Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

  • Read more about Accelerate Diagnostics' insider trading history.
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AXDX Stock News Headlines

Accelerate Diagnostics Delays Q2 2025 Report
Missed the Last 10,000% Surge? Here’s Your Next Chance
Axcelis Technologies went from $2.50 to $180—a staggering 7,100% return. These are the kinds of small-cap breakouts Fierce Analyst aims to catch before they go mainstream. Our research team uses data and trend analysis to uncover high-potential stocks early. And now, you can get free alerts on the next set of breakout candidates—before the crowd rushes in.tc pixel
See More Headlines

AXDX Stock Analysis - Frequently Asked Questions

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its quarterly earnings results on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.13. The medical research company had revenue of $2.82 million for the quarter, compared to analyst estimates of $3 million.

Accelerate Diagnostics shares reverse split on the morning of Wednesday, July 12th 2023.The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/20/2025
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:AXDX
CIK
727207
Employees
220
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.62 million
Net Margins
-471.83%
Pretax Margin
-444.14%
Return on Equity
N/A
Return on Assets
-191.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.50
Quick Ratio
1.34

Sales & Book Value

Annual Sales
$11.70 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.37) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
25,210,000
Free Float
14,125,000
Market Cap
$857 thousand
Optionable
Optionable
Beta
0.22

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AXDX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners